Cabaletta Bio Inc. Common Stock is a clinical-stage biotechnology company focused on the development of novel cell therapies for the treatment of B cell-mediated autoimmune diseases. Its proprietary technology platform utilizes chimeric autoantibody receptor (CAAR) T cells to selectively eliminate B cells activated by these diseases.
